Quarterly Activities Report and Appendix 4C

• Proposed pivotal merger with Cannatrek announced, creating a leading medicinal cannabis group
• Record revenue of $10.7 million, up over 10% on prior period
• Cash receipts of $11.0 million, up nearly 10% on prior corresponding period

Little Green Pharma Ltd (ASX: LGP) has reported its quarterly activities and Appendix 4C for the period ending 31 December 2025. The key highlights include:- Proposed pivotal merger with Cannatrek announced post-quarter end, creating a leading, fully vertically integrated medicinal cannabis group with operations spanning cultivation, manufacturing, and distribution in Australia and Europe. The combined group would have had $112.3 million in revenue, $13.0 million in Adjusted EBITDA, and $14.9 million in cash for the 2025 financial year.- Record revenue of $10.7 million (unaudited), up over 5% on the prior quarter and over 10% on the prior corresponding period. This was driven by strong performance across the company's product portfolio, including a $0.6 million oil shipment to France.- Cash receipts of $11.0 million, up nearly 10% on the prior corresponding period but down slightly on the prior period due to timing of deliveries and payment terms.- Continued growth in the company's European operations, with sales to Europe up 30% on the prior quarter. The company also provided updates on the regulatory environment in key European markets like Germany and Spain.- Launch of new Indicare oils range and strong growth in LGP and CherryCo branded edibles during the quarter.- Significant milestone in US cannabis policy with the US President signing an Executive Order to reschedule cannabis from Schedule I to Schedule III.